163 related articles for article (PubMed ID: 32060883)
1. Nanostructured lipid carrier co-delivering tacrolimus and TNF-α siRNA as an innovate approach to psoriasis.
Viegas JSR; Praça FG; Caron AL; Suzuki I; Silvestrini AVP; Medina WSG; Del Ciampo JO; Kravicz M; Bentley MVLB
Drug Deliv Transl Res; 2020 Jun; 10(3):646-660. PubMed ID: 32060883
[TBL] [Abstract][Full Text] [Related]
2. Tacrolimus and curcumin co-loaded liposphere gel: Synergistic combination towards management of psoriasis.
Jain A; Doppalapudi S; Domb AJ; Khan W
J Control Release; 2016 Dec; 243():132-145. PubMed ID: 27725194
[TBL] [Abstract][Full Text] [Related]
3. Comparative assessment of efficacy and safety potential of multifarious lipid based Tacrolimus loaded nanoformulations.
Jain S; Addan R; Kushwah V; Harde H; Mahajan RR
Int J Pharm; 2019 May; 562():96-104. PubMed ID: 30902706
[TBL] [Abstract][Full Text] [Related]
4. TNFα siRNA delivery by nanoparticles and photochemical internalization for psoriasis topical therapy.
Suzuki IL; de Araujo MM; Bagnato VS; Bentley MVLB
J Control Release; 2021 Oct; 338():316-329. PubMed ID: 34437914
[TBL] [Abstract][Full Text] [Related]
5. Dithranol-loaded nanostructured lipid carrier-based gel ameliorate psoriasis in imiquimod-induced mice psoriatic plaque model.
Sathe P; Saka R; Kommineni N; Raza K; Khan W
Drug Dev Ind Pharm; 2019 May; 45(5):826-838. PubMed ID: 30764674
[TBL] [Abstract][Full Text] [Related]
6. Dendrimer as a new potential carrier for topical delivery of siRNA: A comparative study of dendriplex vs. lipoplex for delivery of TNF-α siRNA.
Pandi P; Jain A; Kommineni N; Ionov M; Bryszewska M; Khan W
Int J Pharm; 2018 Oct; 550(1-2):240-250. PubMed ID: 30165098
[TBL] [Abstract][Full Text] [Related]
7. Improved topical delivery of tacrolimus: A novel composite hydrogel formulation for the treatment of psoriasis.
Gabriel D; Mugnier T; Courthion H; Kranidioti K; Karagianni N; Denis MC; Lapteva M; Kalia Y; Möller M; Gurny R
J Control Release; 2016 Nov; 242():16-24. PubMed ID: 27639683
[TBL] [Abstract][Full Text] [Related]
8. Dual roles of TPGS based microemulsion for tacrolimus: Enhancing the percutaneous delivery and anti-psoriatic efficacy.
Wan T; Pan J; Long Y; Yu K; Wang Y; Pan W; Ruan W; Qin M; Wu C; Xu Y
Int J Pharm; 2017 Aug; 528(1-2):511-523. PubMed ID: 28629978
[TBL] [Abstract][Full Text] [Related]
9. Psoralen loaded liposomal nanocarriers for improved skin penetration and efficacy of topical PUVA in psoriasis.
Doppalapudi S; Jain A; Chopra DK; Khan W
Eur J Pharm Sci; 2017 Jan; 96():515-529. PubMed ID: 27777066
[TBL] [Abstract][Full Text] [Related]
10. Using Imiquimod-Induced Psoriasis-Like Skin as a Model to Measure the Skin Penetration of Anti-Psoriatic Drugs.
Lin YK; Yang SH; Chen CC; Kao HC; Fang JY
PLoS One; 2015; 10(9):e0137890. PubMed ID: 26355594
[TBL] [Abstract][Full Text] [Related]
11. Liposomal tacrolimus lotion as a novel topical agent for treatment of immune-mediated skin disorders: experimental studies in a murine model.
Erdogan M; Wright JR; McAlister VC
Br J Dermatol; 2002 Jun; 146(6):964-7. PubMed ID: 12072063
[TBL] [Abstract][Full Text] [Related]
12. Topical Nanostructured Lipid Carrier Based Hydrogel of Mometasone Furoate for the Treatment of Psoriasis.
Kaur N; Sharma K; Bedi N
Pharm Nanotechnol; 2018; 6(2):133-143. PubMed ID: 29788899
[TBL] [Abstract][Full Text] [Related]
13. How Effective Is Tacrolimus in the Imiquimod-Induced Mouse Model of Psoriasis?
Pischon H; Radbruch M; Ostrowski A; Schumacher F; Hönzke S; Kleuser B; Hedtrich S; Fluhr JW; Gruber AD; Mundhenk L
J Invest Dermatol; 2018 Feb; 138(2):455-458. PubMed ID: 28947356
[No Abstract] [Full Text] [Related]
14. Preparation, characterization, and
Walunj M; Doppalapudi S; Bulbake U; Khan W
J Liposome Res; 2020 Mar; 30(1):68-79. PubMed ID: 30897993
[TBL] [Abstract][Full Text] [Related]
15. Tacrolimus-loaded chitosan nanoparticles for enhanced skin deposition and management of plaque psoriasis.
Fereig SA; El-Zaafarany GM; Arafa MG; Abdel-Mottaleb MMA
Carbohydr Polym; 2021 Sep; 268():118238. PubMed ID: 34127220
[TBL] [Abstract][Full Text] [Related]
16. Effects of nanoparticles with hydrotropic nicotinamide on tacrolimus: permeability through psoriatic skin and antipsoriatic and antiproliferative activities.
Wan T; Pan W; Long Y; Yu K; Liu S; Ruan W; Pan J; Qin M; Wu C; Xu Y
Int J Nanomedicine; 2017; 12():1485-1497. PubMed ID: 28260894
[TBL] [Abstract][Full Text] [Related]
17. Improved tacrolimus skin permeation by co-encapsulation with clobetasol in lipid nanoparticles: Study of drug effects in lipid matrix by electron paramagnetic resonance.
Andrade LM; Silva LAD; Krawczyk-Santos AP; Amorim ICSM; Rocha PBRD; Lima EM; Anjos JLV; Alonso A; Marreto RN; Taveira SF
Eur J Pharm Biopharm; 2017 Oct; 119():142-149. PubMed ID: 28627400
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic anti-psoriatic effects of myeloid-derived suppressor cells in combination with systemic tacrolimus (FK-506) in an imiquimod-induced mouse model of psoriasis.
Park MY; Choo YK; Jeon SH; Jang WG; Lee JH; Park JH; Kim CH
Int Immunopharmacol; 2020 Sep; 86():106553. PubMed ID: 32563057
[TBL] [Abstract][Full Text] [Related]
19. Design & development of nanosponge loaded topical gel of curcumin and caffeine mixture for augmented treatment of psoriasis.
Iriventi P; Gupta NV; Osmani RAM; Balamuralidhara V
Daru; 2020 Dec; 28(2):489-506. PubMed ID: 32472531
[TBL] [Abstract][Full Text] [Related]
20. Novel amphiphilic lipid augments the co-delivery of erlotinib and IL36 siRNA into the skin for psoriasis treatment.
Boakye CHA; Patel K; Doddapaneni R; Bagde A; Marepally S; Singh M
J Control Release; 2017 Jan; 246():120-132. PubMed ID: 27170227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
